Padraig O'Suilleabhain, M.D.

Half way through his medical education in Dublin Ireland, Padraig O’Suilleabhain came to Mayo Clinic in Rochester Minnesota for an elective rotation in neurology. Hugely impressed with the training program, he returned 1992-1998 for neurology residency and for fellowships in movement disorders and clinical research. He then joined the faculty of UT Southwestern Medical Center, where in due course he was promoted to Professor. His duties encompass teaching, administration, patient care, and research. Some high points of each are noted here:

• Dr. O’Suilleabhain is a mentor within UT Southwestern’s colleges program. He is assigned a group of 6 incoming medical students most years, and meets with them frequently during the course of their 4 years of study, training them in clinical skills and professional ethical behaviors.
• Elected to Executive Committee of the Board of the UT Southwestern Medical Group - which is the faculty practice plan – he participates in strategic planning for the Group.
• Caring for patients remains the primary identity and passion of Dr. O’Suilleabhain. He has particular focus on treatment of Parkinson disease, dystonia, and more recently normal pressure hydrocephalus. Most of his time is face to face with someone struggling with a brain disease, trying to help the person and the caregivers get the best treatment and outcomes currently available.
• There is need and opportunity for better treatments in the future. One of his research projects currently involves sifting through the magnetoencephalographic signals generated during skilled activities such as writing, and how this is altered in dystonia and movement disorders. Another project aims to identify factors to guide treatment of normal pressure hydrocephalus He also investigates new treatments for parkinsonism and other diseases of the basal ganglia.

Dr. O’Suilleabhain is a member of the American Academy of Neurology, the American Neurological Association, the International Parkinson and Movement Disorder Society among others.

Medical School

University of Dublin (1991)

Internship

St. James's Hospital (1992), Medicine

Internship

Mayo Clinic School of Graduate Medical Education (1993), Medicine

Residency

Mayo Clinic School of Graduate Medical Education (1996), Neurology

Fellowship

Mayo Clinic School of Graduate Medical Education (1997), Movement Disorders

Research Fellowship

Mayo Clinic School of Graduate Medical Education (1998), Neurology

Other Post Graduate Training

The University of Texas at Dallas (2015), Health Sector Management

• Deep brain stimulation for treatment of tremor
• Huntington disease disease modification
• Magnetoencephalography investigating motor control in normal writing and dystonic writing
• Neuroprotection / disease modification in Progressive Supranuclear Palsy
• Parkinson disease pharmacotherapy

Featured Publications

Yet another way to lower homocysteine: close the Patent Foramen Ovale

O'Suilleabhain, Padraig Neurology 2021 2 97 55-56

Safety and Tolerability of SRX246, a Vasopressin 1a Antagonist, in Irritable Huntington's Disease Patients-A Randomized Phase 2 Clinical Trial.

Brownstein MJ, Simon NG, Long JD, Yankey J, Maibach HT, Cudkowicz M, Coffey C, Conwit RA, Lungu C, Anderson KE, Hersch SM, Ecklund DJ, Damiano EM, Itzkowitz DE, Lu S, Chase MK, Shefner JM, McGarry A, Thornell B, Gladden C, Costigan M, O'Suilleabhain P, Marshall FJ, Chesire AM, Deritis P, Adams JL, Hedera P, Lowen K, Rosas HD, Hiller AL, Quinn J, Keith K, Duker AP, Gruenwald C, Molloy A, Jacob C, Factor S, Sperin E, Bega D, Brown ZR, Seeberger LC, Sung VW, Benge M, Kostyk SK, Daley AM, Perlman S, Suski V, Conlon P, Barrett MJ, Lowenhaupt S, Quigg M, Perlmutter JS, Wright BA, Most E, Schwartz GJ, Lamb J, Chuang RS, Singer C, Marder K, Moran JA, Singleton JR, Zorn M, Wall PV, Dubinsky RM, Gray C, Drazinic C, J Clin Med 2020 Nov 9 11

Safety of the tau-directed monoclonal antibody BIIB092 in progressive supranuclear palsy: a randomised, placebo-controlled, multiple ascending dose phase 1b trial.

Boxer AL, Qureshi I, Ahlijanian M, Grundman M, Golbe LI, Litvan I, Honig LS, Tuite P, McFarland NR, O'Suilleabhain P, Xie T, Tirucherai GS, Bechtold C, Bordelon Y, Geldmacher DS, Grossman M, Isaacson S, Zesiewicz T, Olsson T, Muralidharan KK, Graham DL, O'Gorman J, Haeberlein SB, Dam T, Lancet Neurol 2019 Jun 18 6 549-558

A randomized, double-blind, placebo-controlled trial of coenzyme Q10 in Huntington disease.

McGarry A, McDermott M, Kieburtz K, de Blieck EA, Beal F, Marder K, Ross C, Shoulson I, Gilbert P, Mallonee WM, Guttman M, Wojcieszek J, Kumar R, LeDoux MS, Jenkins M, Rosas HD, Nance M, Biglan K, Como P, Dubinsky RM, Shannon KM, O'Suilleabhain P, Chou K, Walker F, Martin W, Wheelock VL, McCusker E, Jankovic J, Singer C, Sanchez-Ramos J, Scott B, Suchowersky O, Factor SA, Higgins DS, Molho E, Revilla F, Caviness JN, Friedman JH, Perlmutter JS, Feigin A, Anderson K, Rodriguez R, McFarland NR, Margolis RL, Farbman ES, Raymond LA, Suski V, Kostyk S, Colcher A, Seeberger L, Epping E, Esmail S, Diaz N, Fung WL, Diamond A, Frank S, Hanna P, Hermanowicz N, Dure LS, Cudkowicz M Neurology 2016 Dec

Elevated serum pesticide levels and risk of Parkinson disease.

Richardson JR, Shalat SL, Buckley B, Winnik B, O'Suilleabhain P, Diaz-Arrastia R, Reisch J, German DC Arch. Neurol. 2009 Jul 66 7 870-5

Clinical course in Parkinson's disease with elevated homocysteine.

O'Suilleabhain PE, Oberle R, Bartis C, Dewey RB, Bottiglieri T, Diaz-Arrastia R Parkinsonism Relat. Disord. 2006 Mar 12 2 103-7

Movement disorders after head injury: diagnosis and management.

O’Suilleabhain P, Dewey RB Jr. The Journal of head trauma rehabilitation July 2004 19(4) 305-13

Elevated plasma homocysteine level in patients with Parkinson disease: motor, affective, and cognitive associations.

O’Suilleabhain PE, Sung V, Hernandez C, Lacritz L, Dewey RB Jr, Bottiglieri T, Diaz-Arrastia R. Archives of neurology June 2004 61 (6) 865-8

Elevated plasma homocysteine level in patients with Parkinson disease: motor, affective, and cognitive associations.

O'Suilleabhain PE, Sung V, Hernandez C, Lacritz L, Dewey RB, Bottiglieri T, Diaz-Arrastia R Arch. Neurol. 2004 Jun 61 6 865-8

Levodopa elevates homocysteine: is this a problem?

O’Suilleabhain P, Diaz-Arrastia R. Archives of neurology May 2004 61(5) 633-4

 Featured Books

Sensory disturbance in Parkinson's disease. In Parkinson's Disease (Second Edition)

O'Suilleabhain PE (2013). Boca Raton, CRC Press LLC

Adjunctive therapies in Parkinson?s disease. In Parkinson?s Disease and Movement Disorders: Diagnosis and Treatment Guidelines for the Practicing Physician

O'Suilleabhain PE, Murphy SM (2000). Humana Press

Sensory Disturbance in Parkinson's disease. In Parkinson's Disease

O'Suilleabhain PE (2005). Boca Raton, CRC Press LLC

Chorea. In Handbook of Movement Disorders

O'Suilleabhain PE (2011). New York, Oxford American Neurology Library

• Dystonia Doctors of Excellence Award
  from US Dystonia Medical Research Foundation (2004)
• Teaching award
  Voted by 1st year medical students (2001)
• Trephined skull
  Voted teacher of the year by neurology residents (1999)
• Upjohn Prize
  First place in medical school microbiology finals (1988)

• American Association of Neurologists
• American Medical Association
• Dallas County Medical Society
• Movement Disorder Society
• Texas Neurological Association